U.S. Stock News

NasdaqGS:LIVN
NasdaqGS:LIVNMedical Equipment

What LivaNova (LIVN)'s KeyBanc Upgrade and Medtech Reassessment Means For Shareholders

In late January 2026, KeyBanc Capital Markets upgraded its rating on LivaNova PLC to Overweight, citing sustainable underlying trends in the Medical Technology segment and a reduced valuation premium. This shift, alongside Goldman Sachs maintaining coverage with a Neutral stance, highlights increasing institutional focus on how LivaNova fits into the broader medtech landscape. Next, we’ll explore how KeyBanc’s upgraded view on LivaNova’s position within Medical Technology could influence...
NYSE:PAGS
NYSE:PAGSDiversified Financial

Is Renewed Bullish Analyst Coverage Altering The Investment Case For PagSeguro Digital (PAGS)?

In recent days, PagSeguro Digital has drawn increased attention after multiple brokerage firms reiterated positive ratings and refreshed their views on the company. This cluster of supportive analyst opinions has reinforced broader market perception of PagSeguro Digital as a business with improving sentiment among research houses. We’ll now explore how this wave of optimistic analyst coverage could influence PagSeguro Digital’s investment narrative for investors. Uncover the next big...
NasdaqGS:SIGI
NasdaqGS:SIGIInsurance

Selective Insurance Group (SIGI) Underwriting Improvement Challenges Cautious Earnings Narratives

Selective Insurance Group (SIGI) just wrapped up FY 2025 with fourth quarter revenue of US$1.36b and basic EPS of US$2.52, alongside trailing twelve month revenue of US$5.34b and EPS of US$7.48. Over recent periods, the company has seen quarterly revenue move from US$1.26b in Q4 2024 to US$1.36b in Q4 2025, with basic EPS across those same quarters shifting from US$1.52 to US$2.52. The trailing net profit margin is now 8.6% compared with 4.1% a year earlier, and earnings growth over the past...
NYSE:HRB
NYSE:HRBConsumer Services

New H&R Block Directors Add Consumer Focus To Discounted Valuation Story

H&R Block (NYSE:HRB) has appointed Geralyn R. Breig, Christian H. Charnaux, and Stephanie C. Plaines to its Board of Directors. The three executives bring experience in consumer branding, growth planning, finance, and digital business models. The appointments represent a material change in the company’s governance and leadership structure. H&R Block’s share price is currently $39.45, with a 1-year return of 26.4% and a 5-year return of 145.4%. In the nearer term, the stock shows a 1.5%...
NYSE:TWO
NYSE:TWOMortgage REITs

Two Harbors Dividend Tax Clarification And Valuation Gap For 2025

Two Harbors Investment, NYSE:TWO, has released tax treatment details for its 2025 common and preferred dividend distributions. The company stated that no portion of these 2025 distributions is expected to be classified as excess inclusion income. This clarification is intended to guide shareholders as they prepare tax reporting for the 2025 calendar year. For current holders of NYSE:TWO, the update comes with the stock recently trading at $11.47 and showing a mix of short term volatility...
NYSE:CFR
NYSE:CFRBanks

Cullen/Frost Bankers (CFR) Net Interest Margin Holds At 3.66% Challenging Bearish Narratives

Cullen/Frost Bankers (CFR) has just wrapped up FY 2025 with fourth quarter revenue of US$569.6 million and basic EPS of US$2.59, alongside net income of US$164.6 million and a reported net interest margin of 3.66%. Over the past few quarters the company has seen revenue move from US$520.2 million and EPS of US$2.37 in Q4 2024 to US$569.6 million and US$2.59 in Q4 2025. Trailing twelve month EPS stands at US$10.02 on revenue of about US$2.2 billion, and the current focus is on how durable...
NasdaqGS:NAVI
NasdaqGS:NAVIConsumer Finance

Is It Time To Reassess Navient (NAVI) After Recent Share Price Slide

If you are wondering whether Navient is priced attractively right now, the recent share moves and current valuation metrics give you quite a bit to think about. The stock recently closed at US$9.81, with returns of an 18.8% decline over 7 days, a 24.5% decline over 30 days, a 23.2% decline year to date and a 24.7% decline over the past year, alongside a 41.1% decline over 3 years and a 3.2% decline over 5 years. These moves have been unfolding against a backdrop of ongoing market attention...
NYSE:OGN
NYSE:OGNPharmaceuticals

Organon Draws Sun Offer As NEXPLANON Decision Reframes Value Debate

Sun Pharmaceutical has submitted a nonbinding offer to acquire Organon (NYSE:OGN). Organon recently received FDA approval for extended duration use of NEXPLANON with a new REMS safety program. These developments affect Organon’s women’s health portfolio and potential ownership structure. Organon, trading at $8.54, is coming into focus as both a deal target and a women’s health player with a newly approved product label. The share price is up 19.1% over the past 30 days and 18.0% year to...